** Gene therapy developer Regenxbio's RGNX.O shares rise 4.5% to $8.15
** Co reports interim early-stage data for its experimental gene therapy, RGX-202, for the treatment of Duchenne muscular dystrophy (DMD)
** DMD causes skeletal and heart muscle weakness that quickly worsens with time
** The interim data from two additional patients, including one aged 3 years, builds on the favorable safety and efficacy profile seen in ages 4 and older - RGNX
** Co says there were no serious adverse events
** Co plans to share further functional early-stage data in H1 2025
** Including session gains, RGNX has fallen 63% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.